

## Neos Therapeutics, Inc. Appoints Thomas P. McDonnell as Chief Commercial Officer

*Dallas/Fort Worth, TX (April 28, 2015)* – **Neos Therapeutics, Inc.** (“Neos” or “the Company”), a pharmaceutical company with a late-stage pipeline of innovative extended-release (“XR”) product candidates for the treatment of Attention-Deficit Hyperactivity Disorder (“ADHD”), today announced the appointment of Thomas P. McDonnell, to the role of Chief Commercial Officer, effective immediately.

Prior to joining Neos, Mr. McDonnell spent 10 years with Shire (NASDAQ: SHPG), most recently as Vice President of US Marketing in the Neuroscience Business Unit from December 2013 to March 2015. In this role, he led the US Product Strategy Team responsible for the commercialization of Vyvanse and Intuniv into the ADHD market. From August 2012 to November 2013, he was Vice President, General Manager of Adult Psychiatry and led the product strategy team for all commercial and clinical development of Vyvanse in Major Depressive Disorder and Binge Eating Disorder. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR.

Before joining Shire, Mr. McDonnell held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals from 1997 to 2005. He received his B.A. in Marketing from Muhlenberg College.

“I am very excited to welcome Tom to the Neos team. His wealth of experience in commercializing and marketing innovative therapeutic products for the treatment of ADHD, combined with his strong leadership and strategic planning skills, strengthen the management team at a key time in our development as a company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Neos. “We look forward to his contributions as we prepare for the potential launches of our methylphenidate XR-ODT, NT-0102, amphetamine XR-ODT, NT-0202, and amphetamine XR Liquid Suspension, NT-0201, ADHD medications based on Neos’ patented XR-ODT or XR Liquid Suspension technology.”

### About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform. The Company is initially focusing on ADHD with three branded product candidates which are extended-release, or XR, medications in patient-friendly, oral disintegrating tablets or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex® an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

### CONTACTS:

Vipin K. Garg, Ph.D.  
President and CEO  
Neos Therapeutics  
(919) 434-6643

[vgarg@neostx.com](mailto:vgarg@neostx.com)

Richard I. Eisenstadt  
Chief Financial Officer  
Neos Therapeutics  
(972) 408-1389  
[reisenstadt@neostx.com](mailto:reisenstadt@neostx.com)

April 28, 2015